Stockscreener 앱 받기
25.82
22.14%
4.68
전일 마감가:
$21.14
열려 있는:
$24.475
하루 거래량:
24.04M
Relative Volume:
3.27
시가총액:
$17.96B
수익:
$125.68M
순이익/손실:
$4.81B
주가수익비율:
4.5699
EPS:
5.65
순현금흐름:
$-781.21M
1주 성능:
+19.43%
1개월 성능:
+19.48%
6개월 성능:
+121.63%
1년 성능:
+137.53%
1일 변동 폭
$23.97
$25.95
1주일 범위
$20.98
$25.95
52주 변동 폭
$8.73
$25.95
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
25.82 | 14.70B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-02 | 개시 | Citigroup | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Roivant signals multiple pivotal trial readouts and accelerates brepocitinib phase III launch in 2026 - MSN
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative - simplywall.st
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday - TechStock²
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript - Insider Monkey
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress - Finviz
Roivant Sciences earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
10 Easy Double-Digit Gainers - Insider Monkey
Roivant Sciences Q3 2026 Earnings Call Transcript - MarketBeat
Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade) - Seeking Alpha
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum - Investing.com Nigeria
Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss - simplywall.st
Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Earnings call transcript: Roivant Sciences misses Q3 2026 estimates despite stock surge - Investing.com Nigeria
Why Is Roivant Stock Trading Higher Today?Roivant Sciences (NASDAQ:ROIV) - Benzinga
Roivant Sciences Q3 Earnings Call Highlights - Yahoo Finance
Immunovant Q3 Earnings Call Highlights - Yahoo Finance
ROIV: Strong phase II data for brepocitinib in cutaneous sarcoidosis; multiple pivotal readouts ahead - TradingView
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum By Investing.com - Investing.com South Africa
Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib - Nasdaq
Roivant Sciences stock soars after positive cutaneous sarcoidosis trial data By Investing.com - Investing.com Australia
Pfizer-backed Priovant posts positive data for lead asset (PFE) - Seeking Alpha
Roivant Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Priovant announces positive phase 2 results for brepocitinib in cutaneous sarcoidosis (Cs) - marketscreener.com
Roivant Sciences Ltd. SEC 10-Q Report - TradingView
Roivant Sciences Ltd. (ROIV) Misses Q3 EPS by 7c - StreetInsider
Roivant Sciences Swings to Fiscal Q3 Loss as Revenue Falls - marketscreener.com
Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q3 Net Loss $0.38 a Share, vs. FactSet Est of $0.30 Loss - marketscreener.com
Roivant Sciences Ltd. Reports Positive Phase 2 Results and Financial Performance for Q3 2025 - TradingView
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 - The Manila Times
Roivant’s brepocitinib delivers rapid, sustained remissions in cutaneous sarcoidosis — first positive placebo-controlled trial - stocktitan.net
All eyes on Roivant earnings ahead of key drug trial readouts By Investing.com - Investing.com South Africa
All eyes on Roivant earnings ahead of key drug trial readouts - Investing.com Australia
Examining the Future: Roivant Sciences's Earnings Outlook - Benzinga
Understanding Momentum Shifts in (ROIV) - Stock Traders Daily
Short Interest in Roivant Sciences Ltd. (NASDAQ:ROIV) Increases By 25.3% - MarketBeat
Market Recap: Can Roivant Sciences Ltd sustain earnings growthJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Movement Recap: Whats the fair value of Roivant Sciences Ltd stockMarket Sentiment Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Roivant Sciences (ROIV) to Release Quarterly Earnings on Friday - MarketBeat
Is Roivant Sciences Ltd. benefiting from innovation trends2025 Retail Activity & Technical Buy Zone Confirmation - Mfd.ru
Revenue Check: Can Roivant Sciences Ltd generate free cash flowPortfolio Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth - Seeking Alpha
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring the 19.57% Potential Upside in a High-Stakes Biotech Sector - DirectorsTalk Interviews
Avoiding Lag: Real-Time Signals in (ROIV) Movement - Stock Traders Daily
Y Intercept Hong Kong Ltd Buys 601,178 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 - marketscreener.com
Parkside Financial Bank & Trust Has $10.57 Million Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Campbell & CO Investment Adviser LLC Sells 68,705 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Growth Value: Will GOOS benefit from geopolitical trendsInflation Watch & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report - Sahm
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
1.25%
자본화:
|
볼륨(24시간):